Global Immuno Oncology Market
Global Immuno Oncology Market

Immuno Oncology Comprehensive Study by End Users (Hospitals, Clinics, Others), Therapy Type (Checkpoint Inhibitors & Immunomodulators, Cancer Vaccines, Oncolytic Virus, Others), Therapy Area (Lung Cancer, Bladder Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Liver Cancer, Other Cancers) Players and Region - Global Market Outlook to 2025

Immuno Oncology Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025 | CAGR: 13.81%  

Feb 2021 Edition 247 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Immuno Oncology Market Scope
Immuno-oncology therapy can provide more durable clinical outcomes than traditional therapies such as chemotherapy and radiotherapy and in some cases contribute to complete tumor regression. Immuno-oncology therapies also pose a less detrimental impact on patientsí quality of life due to a lower incidence of serious adverse events. Moreover, the rising number of cancer cases worldwide is one of the major factors aiding the growth of the market. Amid the lockdown across different regions, patients suffering from cancer were expected to be at a higher risk, due to the COVID-19 which has also made it difficult to manage the cancer care delivery system. So the requirement of oncologists to be more attentive to detect coronavirus infection early, as any type of advanced cancer is at much higher risk for unfavorable outcomes for the patients. Moreover, due to the lockdown across different countries, the patients were not able to travel from one place to another for their treatment which has led to a slight disparity in cancer care across different regions. Therefore, the global immuno-oncology market is expected to witness a slight decline in its y-o-y growth during the FY-2020 compared to FY 2019 which is again expected to regain its positive growth in FY 2021.

The Immuno Oncology market study is segmented and major geographies with country level break-up.

The Players having a strong hold in the market are F. Hoffmann-La Roche Ltd. Merck & Co., Inc Bristol-Myers Squibb Company Novartis AG Pfizer Inc.. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Immuno Oncology market throughout the predicted period.

Amgen Inc. (United States), AstraZeneca (United Kingdom), Bristol Myers Squibb (United States), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi (France), Merck KGaA (Germany), Incyte (United States) and GlaxoSmithKline plc (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Eli Lilly and Company (United States), Johnson & Johnson Services, Inc. (United States), AbbVie Inc. (United States), Gilead Sciences, Inc. (United States), Aduro Biotech Inc. (United States), SELLAS Life Sciences Group Ltd (United States), Celldex Therapeutics (United States) and BeiGene (China).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Immuno Oncology market by Type, Application and Region. On the basis of Type, Checkpoint Inhibitors & Immunomodulators are dominating the market in the year 2019 where as Cancer Vaccines stood as second largest market share.

On the basis of application, Hospitals segment is dominating the market in the year 2019

On the basis of geography, the market of Immuno Oncology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). NA region held largest market share in the year 2019. Asia Pacific on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Market Leaders and their expansionary development strategies
In September 2020, AstraZeneca has entered into an agreement with Dogma Therapeutics to acquire its preclinical oral PCSK9 inhibitor programme. With this acquisition, it aims to take the programme forward into clinical development for dyslipidaemia, or abnormal amount of lipids in the blood, and familial hypercholesterolemia, a common genetic condition that causes high cholesterol
In January 2020, Pfizer Inc. announced the launch of its Vaccines Divisionís Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific vaccine-preventable diseases and potentially evaluate vaccine effectiveness affecting adults.
FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins and some nucleic acids.

Market Trend
  • Technological Advancement Propelled by Adoption of Next Generation Cancer Treatment

Market Drivers
  • Growing Incidence of Cancer Across the World
  • Growing Healthcare Infrastructure Across Developing Regions

Opportunities
  • Rising Investments in Development of Cancer Drugs & Treatment


Challenges
  • Challenges in Immuno-Oncology Trials


Key Target Audience
Laboratories & Research Institutes, Pharmaceutical Companies, End-Use Industries and Others

Frequently asked questions:
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Immuno Oncology Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2025.

3. What is expected growth rate?
According to AMA, the Global Immuno Oncology market is expected to see growth rate of 13.81%.
Report Objectives / Segmentation Covered
By End Users
  • Hospitals
  • Clinics
  • Others

By Therapy Type
  • Checkpoint Inhibitors & Immunomodulators
  • Cancer Vaccines
  • Oncolytic Virus
  • Others

By Therapy Area
  • Lung Cancer
  • Bladder Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Liver Cancer
  • Other Cancers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Incidence of Cancer Across the World
      • 3.2.2. Growing Healthcare Infrastructure Across Developing Regions
    • 3.3. Market Challenges
      • 3.3.1. Challenges in Immuno-Oncology Trials
    • 3.4. Market Trends
      • 3.4.1. Technological Advancement Propelled by Adoption of Next Generation Cancer Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immuno Oncology, by End Users, Therapy Type, Therapy Area and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Immuno Oncology (Value)
      • 5.2.1. Global Immuno Oncology by: End Users (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Others
      • 5.2.2. Global Immuno Oncology by: Therapy Type (Value)
        • 5.2.2.1. Checkpoint Inhibitors & Immunomodulators
        • 5.2.2.2. Cancer Vaccines
        • 5.2.2.3. Oncolytic Virus
        • 5.2.2.4. Others
      • 5.2.3. Global Immuno Oncology by: Therapy Area (Value)
        • 5.2.3.1. Lung Cancer
        • 5.2.3.2. Bladder Cancer
        • 5.2.3.3. Colorectal Cancer
        • 5.2.3.4. Prostate Cancer
        • 5.2.3.5. Stomach Cancer
        • 5.2.3.6. Liver Cancer
        • 5.2.3.7. Other Cancers
      • 5.2.4. Global Immuno Oncology Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Immuno Oncology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol Myers Squibb (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck KGaA (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Incyte (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Immuno Oncology Sale, by End Users, Therapy Type, Therapy Area and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Immuno Oncology (Value)
      • 7.2.1. Global Immuno Oncology by: End Users (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Others
      • 7.2.2. Global Immuno Oncology by: Therapy Type (Value)
        • 7.2.2.1. Checkpoint Inhibitors & Immunomodulators
        • 7.2.2.2. Cancer Vaccines
        • 7.2.2.3. Oncolytic Virus
        • 7.2.2.4. Others
      • 7.2.3. Global Immuno Oncology by: Therapy Area (Value)
        • 7.2.3.1. Lung Cancer
        • 7.2.3.2. Bladder Cancer
        • 7.2.3.3. Colorectal Cancer
        • 7.2.3.4. Prostate Cancer
        • 7.2.3.5. Stomach Cancer
        • 7.2.3.6. Liver Cancer
        • 7.2.3.7. Other Cancers
      • 7.2.4. Global Immuno Oncology Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immuno Oncology: by End Users(USD Million)
  • Table 2. Immuno Oncology Hospitals , by Region USD Million (2014-2019)
  • Table 3. Immuno Oncology Clinics , by Region USD Million (2014-2019)
  • Table 4. Immuno Oncology Others , by Region USD Million (2014-2019)
  • Table 5. Immuno Oncology: by Therapy Type(USD Million)
  • Table 6. Immuno Oncology Checkpoint Inhibitors & Immunomodulators , by Region USD Million (2014-2019)
  • Table 7. Immuno Oncology Cancer Vaccines , by Region USD Million (2014-2019)
  • Table 8. Immuno Oncology Oncolytic Virus , by Region USD Million (2014-2019)
  • Table 9. Immuno Oncology Others , by Region USD Million (2014-2019)
  • Table 10. Immuno Oncology: by Therapy Area(USD Million)
  • Table 11. Immuno Oncology Lung Cancer , by Region USD Million (2014-2019)
  • Table 12. Immuno Oncology Bladder Cancer , by Region USD Million (2014-2019)
  • Table 13. Immuno Oncology Colorectal Cancer , by Region USD Million (2014-2019)
  • Table 14. Immuno Oncology Prostate Cancer , by Region USD Million (2014-2019)
  • Table 15. Immuno Oncology Stomach Cancer , by Region USD Million (2014-2019)
  • Table 16. Immuno Oncology Liver Cancer , by Region USD Million (2014-2019)
  • Table 17. Immuno Oncology Other Cancers , by Region USD Million (2014-2019)
  • Table 18. South America Immuno Oncology, by Country USD Million (2014-2019)
  • Table 19. South America Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 20. South America Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 21. South America Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 22. Brazil Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 23. Brazil Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 24. Brazil Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 25. Argentina Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 26. Argentina Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 27. Argentina Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 28. Rest of South America Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 29. Rest of South America Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 30. Rest of South America Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 31. Asia Pacific Immuno Oncology, by Country USD Million (2014-2019)
  • Table 32. Asia Pacific Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 33. Asia Pacific Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 34. Asia Pacific Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 35. China Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 36. China Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 37. China Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 38. Japan Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 39. Japan Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 40. Japan Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 41. India Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 42. India Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 43. India Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 44. South Korea Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 45. South Korea Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 46. South Korea Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 47. Taiwan Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 48. Taiwan Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 49. Taiwan Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 50. Australia Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 51. Australia Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 52. Australia Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 53. Rest of Asia-Pacific Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 54. Rest of Asia-Pacific Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 55. Rest of Asia-Pacific Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 56. Europe Immuno Oncology, by Country USD Million (2014-2019)
  • Table 57. Europe Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 58. Europe Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 59. Europe Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 60. Germany Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 61. Germany Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 62. Germany Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 63. France Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 64. France Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 65. France Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 66. Italy Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 67. Italy Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 68. Italy Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 69. United Kingdom Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 70. United Kingdom Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 71. United Kingdom Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 72. Netherlands Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 73. Netherlands Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 74. Netherlands Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 75. Rest of Europe Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 76. Rest of Europe Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 77. Rest of Europe Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 78. MEA Immuno Oncology, by Country USD Million (2014-2019)
  • Table 79. MEA Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 80. MEA Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 81. MEA Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 82. Middle East Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 83. Middle East Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 84. Middle East Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 85. Africa Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 86. Africa Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 87. Africa Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 88. North America Immuno Oncology, by Country USD Million (2014-2019)
  • Table 89. North America Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 90. North America Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 91. North America Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 92. United States Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 93. United States Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 94. United States Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 95. Canada Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 96. Canada Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 97. Canada Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 98. Mexico Immuno Oncology, by End Users USD Million (2014-2019)
  • Table 99. Mexico Immuno Oncology, by Therapy Type USD Million (2014-2019)
  • Table 100. Mexico Immuno Oncology, by Therapy Area USD Million (2014-2019)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Immuno Oncology: by End Users(USD Million)
  • Table 112. Immuno Oncology Hospitals , by Region USD Million (2020-2025)
  • Table 113. Immuno Oncology Clinics , by Region USD Million (2020-2025)
  • Table 114. Immuno Oncology Others , by Region USD Million (2020-2025)
  • Table 115. Immuno Oncology: by Therapy Type(USD Million)
  • Table 116. Immuno Oncology Checkpoint Inhibitors & Immunomodulators , by Region USD Million (2020-2025)
  • Table 117. Immuno Oncology Cancer Vaccines , by Region USD Million (2020-2025)
  • Table 118. Immuno Oncology Oncolytic Virus , by Region USD Million (2020-2025)
  • Table 119. Immuno Oncology Others , by Region USD Million (2020-2025)
  • Table 120. Immuno Oncology: by Therapy Area(USD Million)
  • Table 121. Immuno Oncology Lung Cancer , by Region USD Million (2020-2025)
  • Table 122. Immuno Oncology Bladder Cancer , by Region USD Million (2020-2025)
  • Table 123. Immuno Oncology Colorectal Cancer , by Region USD Million (2020-2025)
  • Table 124. Immuno Oncology Prostate Cancer , by Region USD Million (2020-2025)
  • Table 125. Immuno Oncology Stomach Cancer , by Region USD Million (2020-2025)
  • Table 126. Immuno Oncology Liver Cancer , by Region USD Million (2020-2025)
  • Table 127. Immuno Oncology Other Cancers , by Region USD Million (2020-2025)
  • Table 128. South America Immuno Oncology, by Country USD Million (2020-2025)
  • Table 129. South America Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 130. South America Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 131. South America Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 132. Brazil Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 133. Brazil Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 134. Brazil Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 135. Argentina Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 136. Argentina Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 137. Argentina Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 138. Rest of South America Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 139. Rest of South America Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 140. Rest of South America Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 141. Asia Pacific Immuno Oncology, by Country USD Million (2020-2025)
  • Table 142. Asia Pacific Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 143. Asia Pacific Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 144. Asia Pacific Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 145. China Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 146. China Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 147. China Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 148. Japan Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 149. Japan Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 150. Japan Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 151. India Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 152. India Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 153. India Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 154. South Korea Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 155. South Korea Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 156. South Korea Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 157. Taiwan Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 158. Taiwan Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 159. Taiwan Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 160. Australia Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 161. Australia Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 162. Australia Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 163. Rest of Asia-Pacific Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 164. Rest of Asia-Pacific Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 165. Rest of Asia-Pacific Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 166. Europe Immuno Oncology, by Country USD Million (2020-2025)
  • Table 167. Europe Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 168. Europe Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 169. Europe Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 170. Germany Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 171. Germany Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 172. Germany Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 173. France Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 174. France Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 175. France Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 176. Italy Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 177. Italy Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 178. Italy Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 179. United Kingdom Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 180. United Kingdom Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 181. United Kingdom Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 182. Netherlands Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 183. Netherlands Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 184. Netherlands Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 185. Rest of Europe Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 186. Rest of Europe Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 187. Rest of Europe Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 188. MEA Immuno Oncology, by Country USD Million (2020-2025)
  • Table 189. MEA Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 190. MEA Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 191. MEA Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 192. Middle East Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 193. Middle East Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 194. Middle East Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 195. Africa Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 196. Africa Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 197. Africa Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 198. North America Immuno Oncology, by Country USD Million (2020-2025)
  • Table 199. North America Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 200. North America Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 201. North America Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 202. United States Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 203. United States Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 204. United States Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 205. Canada Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 206. Canada Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 207. Canada Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 208. Mexico Immuno Oncology, by End Users USD Million (2020-2025)
  • Table 209. Mexico Immuno Oncology, by Therapy Type USD Million (2020-2025)
  • Table 210. Mexico Immuno Oncology, by Therapy Area USD Million (2020-2025)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immuno Oncology: by End Users USD Million (2014-2019)
  • Figure 5. Global Immuno Oncology: by Therapy Type USD Million (2014-2019)
  • Figure 6. Global Immuno Oncology: by Therapy Area USD Million (2014-2019)
  • Figure 7. South America Immuno Oncology Share (%), by Country
  • Figure 8. Asia Pacific Immuno Oncology Share (%), by Country
  • Figure 9. Europe Immuno Oncology Share (%), by Country
  • Figure 10. MEA Immuno Oncology Share (%), by Country
  • Figure 11. North America Immuno Oncology Share (%), by Country
  • Figure 12. Global Immuno Oncology share by Players 2019 (%)
  • Figure 13. Global Immuno Oncology share by Players (Top 3) 2019(%)
  • Figure 14. Global Immuno Oncology share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Amgen Inc. (United States) Revenue: by Geography 2019
  • Figure 18. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. AstraZeneca (United Kingdom) Revenue: by Geography 2019
  • Figure 20. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bristol Myers Squibb (United States) Revenue: by Geography 2019
  • Figure 22. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2019
  • Figure 24. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 28. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi (France) Revenue: by Geography 2019
  • Figure 30. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Merck KGaA (Germany) Revenue: by Geography 2019
  • Figure 32. Incyte (United States) Revenue, Net Income and Gross profit
  • Figure 33. Incyte (United States) Revenue: by Geography 2019
  • Figure 34. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2019
  • Figure 36. Global Immuno Oncology: by End Users USD Million (2020-2025)
  • Figure 37. Global Immuno Oncology: by Therapy Type USD Million (2020-2025)
  • Figure 38. Global Immuno Oncology: by Therapy Area USD Million (2020-2025)
  • Figure 39. South America Immuno Oncology Share (%), by Country
  • Figure 40. Asia Pacific Immuno Oncology Share (%), by Country
  • Figure 41. Europe Immuno Oncology Share (%), by Country
  • Figure 42. MEA Immuno Oncology Share (%), by Country
  • Figure 43. North America Immuno Oncology Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Amgen Inc. (United States)
  • AstraZeneca (United Kingdom)
  • Bristol Myers Squibb (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • Merck KGaA (Germany)
  • Incyte (United States)
  • GlaxoSmithKline plc (United Kingdom)
Additional players considered in the study are as follows:
Eli Lilly and Company (United States) , Johnson & Johnson Services, Inc. (United States) , AbbVie Inc. (United States) , Gilead Sciences, Inc. (United States) , Aduro Biotech Inc. (United States) , SELLAS Life Sciences Group Ltd (United States) , Celldex Therapeutics (United States) , BeiGene (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation